Interferon alpha 2b topical - Helix BioPharma

Drug Profile

Interferon alpha 2b topical - Helix BioPharma

Alternative Names: AP-001; Interferon-alpha-2b - Helix BioPharma

Latest Information Update: 29 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Helix BioPharma
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cervical dysplasia; Genital warts

Most Recent Events

  • 23 Dec 2016 Xisle and Altum Pharmaceuticals agree to co-develop interferon alpha 2b for Cervical dysplasia
  • 23 Dec 2016 Xisle Pharma Ventures Trust in-licenses Biphasix™ technology platform, including Interferon alpha 2b topical for the treatment of Cervical dysplasia (HPV-induced), from Helix BioPharma
  • 17 Apr 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top